Evidence map›Paper›PMID 41127195›Full record

ArticleRSC advances2025

Discovery of novel angiotensin-converting enzyme inhibitory peptides by

Fenglin Jiao, Jinlin Yang, Fangfang Wang, Shanli Peng, Bo Zhou

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fenglin JiaoSchool of Life Science, Linyi University Linyi 276000 China yu100288@163.com.
Jinlin YangSchool of Life Science, Linyi University Linyi 276000 China yu100288@163.com.
Fangfang WangSchool of Life Science, Linyi University Linyi 276000 China yu100288@163.com.ORCID https://orcid.org/0000-0003-0309-4199
Shanli PengSchool of Life Science, Linyi University Linyi 276000 China yu100288@163.com.
Bo ZhouState Key Laboratory of Functions and Applications of Medicinal Plants, College of Basic Medical, Guizhou Medical University Guizhou 550004 China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension represents a crucial risk factor in the development of cardiovascular diseases, including heart failure, stroke, coronary heart disease and myocardial infarction. Currently, synthetic angiotensin-converting enzyme (ACE) inhibitors are an important first-line treatment for hypertension. However, these synthetic ACE inhibitors often produce side effects in clinical application, such as cough, gustatory disturbance and skin rash. Thus, it is urgent to find safe and effective ACE inhibitors for the treatment of hypertension. Therefore, a series of ACE inhibitory peptides were studied using computational approaches. Initially, a reliable 3D-QSAR model was derived based on CoMFA (

Identifiers

PMID41127195
PMCPMC12538393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.